> top > docs > PubMed:14449435 > annotations

PubMed:14449435 JSONTXT

Annnotations TAB JSON ListView MergeView

PubmedHPO

Id Subject Object Predicate Lexical cue
T1 613-623 HP_0001882 denotes leukopenia

Inflammaging

Id Subject Object Predicate Lexical cue
T1 0-72 Sentence denotes Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine.
T2 73-75 Sentence denotes 1.
T3 76-228 Sentence denotes 6-Mercaptopurine (6-MP) prevents experimental allergic encephalomyelitis (EAE) during the period of drug administration in both rabbits and guinea pigs.
T4 229-380 Sentence denotes The disease is suppressed even when treatment is started as late as the 5th day after antigenic stimulation in guinea pigs and the 12th day in rabbits.
T5 381-383 Sentence denotes 2.
T6 384-478 Sentence denotes After discontinuation of 6-MP treatment, there is a latent period before the disease is noted.
T7 479-562 Sentence denotes The length of this latent period is not modified by the duration of 6-MP treatment.
T8 563-565 Sentence denotes 3.
T9 566-742 Sentence denotes The effect of 6-MP on EAE is not the result of leukopenia, non-specific toxicity and debilitation, anti-inflammatory activity, or mere masking of clinical signs of the disease.
T10 743-814 Sentence denotes It is, rather, the result of 6-MP's specific anti-immunologic activity.
T11 815-817 Sentence denotes 4.
T12 818-909 Sentence denotes The effects of 6-MP on antibody production, delayed hypersensitivity, and EAE are compared.
T13 910-1012 Sentence denotes This provides indirect evidence for the importance of circulating antibody in the pathogenesis of EAE.
T14 1013-1015 Sentence denotes 5.
T15 1016-1157 Sentence denotes The important considerations in the use of 6-MP are discussed and the possible usefulness of 6-MP in human neurologic diseases is considered.
T1 0-72 Sentence denotes Experimental allergic encephalomyelitis: the effect of 6-mercaptopurine.
T2 73-75 Sentence denotes 1.
T3 76-228 Sentence denotes 6-Mercaptopurine (6-MP) prevents experimental allergic encephalomyelitis (EAE) during the period of drug administration in both rabbits and guinea pigs.
T4 229-380 Sentence denotes The disease is suppressed even when treatment is started as late as the 5th day after antigenic stimulation in guinea pigs and the 12th day in rabbits.
T5 381-383 Sentence denotes 2.
T6 384-478 Sentence denotes After discontinuation of 6-MP treatment, there is a latent period before the disease is noted.
T7 479-562 Sentence denotes The length of this latent period is not modified by the duration of 6-MP treatment.
T8 563-565 Sentence denotes 3.
T9 566-742 Sentence denotes The effect of 6-MP on EAE is not the result of leukopenia, non-specific toxicity and debilitation, anti-inflammatory activity, or mere masking of clinical signs of the disease.
T10 743-814 Sentence denotes It is, rather, the result of 6-MP's specific anti-immunologic activity.
T11 815-817 Sentence denotes 4.
T12 818-909 Sentence denotes The effects of 6-MP on antibody production, delayed hypersensitivity, and EAE are compared.
T13 910-1012 Sentence denotes This provides indirect evidence for the importance of circulating antibody in the pathogenesis of EAE.
T14 1013-1015 Sentence denotes 5.
T15 1016-1157 Sentence denotes The important considerations in the use of 6-MP are discussed and the possible usefulness of 6-MP in human neurologic diseases is considered.